kgromax
8時間前
Hello Yahsho,
you are welcome to post your thoughts, investment thesis and any piece of information related to CYDY here, as long as iHub's policy are followed. These policies are very simple to follow - basically the 4 most common mistakes are to discuss non CYDY-related topics, post insults / complaints about the board moderation, links to / comparisons with other boards, or to try to doxx someone. As long as you follow the policies, I will make sure your voice can be heard here.
I know a significant investment can make things important to someone. But remember: you can always post the facts and your own ideas if you disagree, and the more the better. And also remember: people are free to disagree with you. Their freedom is not limited by yours.
Last, I think you have been scammed. It's called a pump & dump scam. It's very common on OTC markets (and the barrel bottom of the NASDAQ). CYDY has displayed all the signs for years, it's a regular event here. Sky high promises, groups of investors motivating each other, someone coming with all kinds of theories about why this is the miracle company. I have seen hundreds of pump & dumps over the last 20 years and this one follows all the patterns. More information there:
https://www.sec.gov/rss/your_money/pump_and_dump.htm
kgromax
11時間前
LOL, spilled my coffee reading your post.
What planet are you posting from now?
Good news: you can replace your coffee with Leronlimab. Aside from severe diarrhea (the only proven effect of Leronlimab), it should be the same - minus the caffeine.
More seriously, judging by your track record and mine on this board, I stand on planet Earth, and you might want to question yourself.
Now, back to the central topic: Cytodyn. Leronlimab is one of the OLDEST mAb on planet Earth. It comes from the 90's. Sigh. In 30 years, it has been presented at hundreds of conferences, boards, and papers. Yet, it has been approved nowhere, and the feedback from independent scientists has been, well, that it’s better to look elsewhere. Those are FACTS from planet Earth.
So, your conference is just another addition to the heap of destroyed investors’ capital.
Monroe1
11時間前
LOL, spilled my coffee reading your post.
What planet are you posting from now?
Feeling the pinch???? Get used to it like for the past number of months... up up and away.
$$$$CYDY$$$$ 2025 and BEYOND
“As a cancer therapeutic, leronlimab was well tolerated with remarkably infrequent treatment-related adverse events. These promising results suggest further studies with leronlimab are warranted to expand oncology treatment options and improve patient care.” Pestell
CytoDyn ( CYDY ) worked with consultants and key opinion leaders to summarize the findings and submit an abstract to the European Society for Medical Oncology (ESMO) Breast Cancer meeting taking place in Munich, Germany, from May 14 to 17, 2025. Boom da boom as they say.
Dr. Jacob Lalezari, CEO of CytoDyn ( CYDY ), added: "........
I expect the Company’s oncology efforts to accelerate in the coming months, with further announcements in both mTNBC and colorectal cancer.”
Monroe1
11時間前
Welcome back Yahsho. As before your posts have been right on.
" confirmed that a small group of patients who failed treatment after developing metastatic disease survived more than 36 months after receiving leronlimab, are alive today, and currently identify as having no evidence of ongoing disease."
Dr. Jacob Lalezari, CEO of CytoDyn ( CYDY ), added: “These provocative observations of improved survival in patients with mTNBC and prior treatment failure in the metastatic setting, including reported clearance of disease in a group of long-term survivors, provides early clinical evidence of leronlimab’s potential impact in the treatment of TNBC and other solid tumors. I expect the Company’s oncology efforts to accelerate in the coming months, with further announcements in both mTNBC and colorectal cancer.”
Based on these survival observations, the Company has initiated two pre-clinical studies in mTNBC that will evaluate possible treatment synergies between leronlimab, an antibody-drug complex treatment (sacituzumab govitecan), and an immune checkpoint inhibitor (pembrolizumab). The Company will also continue to perform follow-up testing on the group of mTNBC survivors who currently identify as having no evidence of ongoing disease.
Already seems the demand is knocking down the doors at CytoDyn. As word gets out Dr. J may need a security robot!!! 2025 AND BEYOND sin duda.
kgromax
12時間前
Her cancer has metastasized to her spine. Her doctor's could not control her pain. Her cancer had spread too far. Because of this, she chose to discontinue treatment in her third week on Leronlimab. I find it unconscionable that you see fit to drag her case out to try and make your point. Name any treatment that could have saved this woman within three treatments. You can't, because one doesn't exist. You can't fathom the pain she was in!
Excepted I have decided to write this because... there was a full pump around her case!
Everybody was saying that she should take it, that Leronlimab would save her, that it was 100% certain, that it was an obvious miracle, ...
Only a few people had the courage to say that there was no serious medical data to back any of this up, and that she should look for alternative trials.
Yes, that pump was disgusting. Thanks for proving my point
kgromax
13時間前
What's missing is more telling than what is present
This poor PR, or more precisely the lack of any HIV PR today linked to the Gates Foundation, is the proof, right from the company, that the Gates Foundation grant announced Friday was not aimed at Leronlimab nor at Cytodyn.
Otherwise they would have PR'ed it, compared to this half-baked, unrelated one.
PS : and don't get me started on "survival rates that compare favourably". It's very easy to distort these statistical figures, that's what Cytodyn's statisticians have done every previous time for several years now. And every time the results were finally ... rejected for further development.
docj
15時間前
MGK_2
•
9h ago
"Hütter’s Legacy Reload (Germany): Gero Hütter’s Berlin Patient cure—CCR5-delta 32 king, SAB relic. His 2008 win powers LATCH—a murmur from him flips HIV upside down."
"In September 2020, CytoDyn had this press release: https://www.globenewswire.com/news-release/2020/09/01/2086694/0/en/Global-Health-Leaders-Join-CytoDyn-s-Scientific-Advisory-Board.html
In it, CytoDyn "announced the formation and initial members of its Scientific Advisory Board today including leading HIV, NASH, Oncology, and Rheumatological clinical experts and researchers.
CytoDyn's Scientific Advisory Board members include Dr. Gero Hütter, German hematologist, best known for the bone marrow transplant resulting in the cure of the first HIV patient; Dr. Hope S. Rugo, Professor, Department of Medicine (Hematology/Oncology) and Director of the Breast Oncology Clinical Trials Education Program at University of California San Francisco; Dr. Richard T. Maziarz, Professor, Medical Director of the Adult Blood and Marrow Stem Cell Transplant and Cellular Therapy Program Knight Cancer Institute at Oregon Health & Science University (OHSU); Dr. Jonah B. Sacha, Professor, VGTI-Vaccine and Gene Therapy Institute at OHSU; Dr. Mazen Noureddin, a hepatologist and Director, Cedars-Sinai Liver Transplant Program in Los Angeles; Dr. Norman B. Gaylis, nationally and internationally recognized specialist in rheumatology and autoimmune diseases; Dr. Eric D. Mininberg, Oncology Specialist, Piedmont Cancer Institute, a member of the MD Anderson Cancer Network; and Dr. Lishomwa Ndhlovu, Assistant Professor, Immunology, Department of Medicine, Division of Infectious Disease at Weill Cornell Medicine in New York.""
docj
15時間前
MGK_2
•
9h ago
"Montefiore’s Neuro Bet: Beyond oncology, the Einstein/Montefiore preclinicals (March 2024) and Cornell’s Alzheimer’s pilot (December 2024) hint at CCR5’s brain inflammation role. A neurodegeneration win’s a $50B market—CYDY’s dark pool."
"27:15 Nader: Yeah, and BTD that we will be filing, Dr. Nitya Ray did a fantastic job on that. There were some patients with brain metastases*. Dr. Ray, explain to us, for a breakthrough designation strategy, are* we going to file for brain metastases and perhaps later on, if we do get BTD on the original submissions, maybe we want to ask for Basket Trial data, but tell us about the Basket Trial please.
27:60 Nitya Ray: The BTD application that is submitted is 28 patients from 3 different trials. And out of the 28, 6 had brain metastases*. They are* all mTNBC patients*. So we have submitted all of the results,* including all of the patients with brain metastases*, now with the FDA and FDA is reviewing it and we are waiting for FDA to respond for BTD application and we expect to hear from them in about 2 weeks. 2-3 weeks. Our CTA application I believe was submitted on November 5. So by January 5, we should hear from FDA. and then we are going to discuss with FDA and* see that forward with brain metastases*. Now,* these are not the only patients with brain metastases because these are mTNBC patients. But, we have other patients in the Basket Trial and not mTNBC, with brain metastases. And so we are very excited about what is happening with these patients. And so we are going to discuss this with the FDA and we do plan, after we receive the response from the FDA on the BTD application that is submitted, we are going to plan for perhaps another BTD just focusing on the brain metastases."